casanovadp at KillBaitTeplizumab: la EMA recomienda retrasar el inicio de la diabetes tipo 1 en mayores de 8 años
Un logro enorme que ofrece esperanza real a familias afectadas.
dinosauromer at KillBaitTeplizumab: la EMA recomienda retrasar el inicio de la diabetes tipo 1 en mayores de 8 años
Gran avance para la salud.
flareonemory at KillBaitTeplizumab: la EMA recomienda retrasar el inicio de la diabetes tipo 1 en mayores de 8 años
La recomendación de la EMA para Teplizumab representa un avance trascendental en la lucha contra la diabetes tipo 1. Retrasar la aparición de la enfermedad durante más de cuatro años ofrece una esperanza tangible para pacientes y familias, especialmente en la población infantil, mejorando la calidad...
romania at KillBaitTeplizumab: la EMA recomienda retrasar el inicio de la diabetes tipo 1 en mayores de 8 años
La Agencia Europea de Medicamentos (EMA) ha dado un paso histórico hacia la prevención de la diabetes tipo 1 al recomendar la autorización del tratamiento Teplizumab (principio activo teplizumab) para retrasar la aparición de la enfermedad en personas desde los ocho años en estadio 2. Este fármaco, ... [Ver más]
Apotheken UmschauDie amerikanische Arzneimittelbehörde FDA hat im November den Antikörper #Teplizumab zugelassen. Dieser hat in Studien gezeigt, dass er bei noch nicht klinisch manifestem Typ-1-#Diabetes den Krankheitsverlauf verlangsamen kann. Mehr dazu im #Podcast. https://www.apotheken-umschau.de/podcast/episode/ne-dosis-wissen-der-podcast-fuer-health-professionals/neue-hoffnung-bei-typ-1-diabetes-929831.html?utm_source=twitter&utm_medium=social_au&utm_id=929831
Joshua LevyMy blog on the big news of last month. Not a cure, but the first treatment to change the course of #t1d, with a lot of implications for prevention. This especially impacts all siblings of people with #T1 (and other first level relatives). It will delay onset of the honeymoon phase by years.
https://cureresearch4type1diabetes.blogspot.com/2022/12/the-fda-approves-teplizumab-under-name.html #teplizumab #tzield
https://cureresearch4type1diabetes.blogspot.com/2022/12/the-fda-approves-teplizumab-under-name.html #teplizumab #tzield
Mary Murphy 🩼👩💻🌸🪡👩👧👦🇪🇺RTing JDRF Post 17/11/22: 📹 WATCH: Our Director of Research Partnerships @coracle1 explains why we are so excited that @US_FDA has approved #teplizumab as the first disease-modifying drug for #Type1Diabetes. 🎉
Read more: https://jdrf.org.uk/news/worlds-first-type-1-diabetes-disease-modifying-drug-approved-in-the-us/ #T1D #GBDoc #T1Dresearch
ABCDFDA approval for teplizumab (delays stage 3 type 1 diabetes by an average of three years) outside of a research setting.
With ELSA just launched in the UK, these are hopeful times
#Diabetes #DiabetesPrevention #Teplizumab
Links:
https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-can-delay-onset-type-1-diabetes
https://www.diabetes.org.uk/about_us/news/elsa-trial-screen-children-type-1-diabetes
Chris AskewWaking up to last nights great news from the US that a first immunotherapy #teplizumab for #type1 #diabetes has been approved; a stepping stone to further discoveries and new treatments to delay the onset of #type1diabetes https://www.diabetes.org.uk/about_us/news/first-treatment-delay-type-1-diabetes-teplizumab-licensed-us
First ever treatment to delay type 1 diabetes is licensed in the US
The US Food and Drugs Administration (FDA) has approved the world’s first ever immunotherapy for type 1 diabetes, teplizumab, also called Tzield. This is the biggest treatment breakthrough for the condition since the discovery of insulin 100 years ago.